Humacyte presents new data on acellular tissue engineered vessels for dialysis access at VASA

Humacyte presents new data on acellular tissue engineered vessels for dialysis access at VASA
Humacyte shows ATET for dialysis

Humacyte is set to present new scientific research on acellular tissue engineered vessels at the Vascular Access Society of the Americas (VASA) meeting.

The study examines the performance of these vessels after repeated cannulation, which is critical for patients requiring dialysis access. The presentation aims to offer insights into the durability and effectiveness of ATET in clinical settings. Further information is available through the official event channels.

Humacyte recently had its marketing application for the Symvess acellular vessel accepted by the Israel Ministry of Health, starting a 180-day review process. The company has also reported that 20 percent of vascular injury patients arrive at hospitals late, raising the risk of amputation, according to company estimates. These developments provide further context for Humacyte’s ongoing research presentations.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.